Holen Sie sich die Stockscreener-App
0.2327
1.90%
-0.0045
Handel nachbörslich:
.23
-0.0027
-1.16%
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
AIM Should I Buy - Intellectia AI
Maxim Group Maintains AIM ImmunoTech(AIM.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
AIM ImmunoTech Announces Equity Offering to Bolster Capital - TipRanks
AIM ImmunoTech (NYSE: AIM) offers 7.52M shares; private warrants for 15.04M - Stock Titan
AIM ImmunoTech Raises $2.4M in Registered Direct, Adds $4.9M Warrant Upside at $0.325 - TradingView
AIM ImmunoTech (NYSE: AIM) raises $2.4M via stock sale and warrants - Stock Titan
AIM ImmunoTech prices $2.4M registered direct offering By Investing.com - Investing.com South Africa
AIM ImmunoTech prices $2.4M registered direct offering - Investing.com UK
AIM ImmunoTech announces $2.4M registered direct offering - TipRanks
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct ... - Caledonian Record
Press Release: AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement - 富途牛牛
Maxim Group Maintains AIM ImmunoTech(AIM.US) With Buy Rating, Cuts Target Price to $1.5 - Moomoo
AIM Stock Price, Quote & Chart | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM ImmunoTech Inc. has officially suspended its equity distribution agreement and will terminate its continuous offering program effective from May 19, 2026. - Bitget
AIM Immunotech (NYSE American: AIM) suspends ATM program after $2.85M sold - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
AIM ImmunoTech Boosts Stockholder Equity by $11.9 Million and Extends Promissory Note to 2027 to Advance Pancreatic Cancer Strategy 12 - Minichart
AIM ImmunoTech extends debt maturity, reports equity gain By Investing.com - Investing.com South Africa
AIM ImmunoTech announces significant increase in stockholder equity and extension of promissory note maturity date to June 2027 - marketscreener.com
Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027 - TradingView
AIM ImmunoTech Strengthens Equity Position and Financial Flexibility - TipRanks
AIM ImmunoTech Inc. announced an extension to the maturity date of one of its promissory notes. - Bitget
AIM ImmunoTech extends debt maturity, reports equity gain - Investing.com
AIM ImmunoTech Extends Streeterville Promissory Note to 2027; Adds $10,000 Fee, $1.68M Balance - TradingView
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities - The Manila Times
AIM ImmunoTech equity jumps $11.9M, debt pushed to 2027 for pancreatic cancer - Stock Titan
Equity swings positive as AIM ImmunoTech (NYSE: AIM) extends note to 2027 - Stock Titan
AIM ImmunoTech Inc. Amends Promissory Note Agreement With Streeterville Capital and Extends Maturity Date to June 30, 2027 - marketscreener.com
12 Health Care Stocks Moving In Monday's Intraday Session - Sahm
12 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
12 Health Care Stocks Moving In Monday's After-Market SessionAIM ImmunoTech (AMEX:AIM), Atlantic Inter - Benzinga
$AIM ImmunoTech (AIM.US)$ buy sell flyy🔥 - Moomoo
AIM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AIM ImmunoTech (AIM) posts Q1 2026 loss, flags going concern and NYSE equity shortfall - Stock Titan
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer - Sahm
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment - The National Law Review
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader - GlobeNewswire
AIM ImmunoTech Highlights Ampligen’s Positive Phase 2 Data in Late-Stage Pancreatic Cancer and Survival Benefits - Minichart
AIM ImmunoTech Highlights Ampligen Progress in Pancreatic Cancer - TipRanks
AIM ImmunoTech Reports Positive Data from Named Patient Program and Interim Results from Phase 2 Study of Ampligen® for Late-Stage Pancreatic Cancer - Quiver Quantitative
AIM ImmunoTech (NYSE: AIM) showcases Ampligen pancreatic cancer data in KOL segment - Stock Titan
Pancreatic cancer data show 22.3‑month survival gain with Ampligen - Stock Titan
Earnings Scheduled For May 13, 2026 - Benzinga
AIM ImmunoTech Company Profile & Introduction - Moomoo
AIM ImmunoTech raises $3.6 million through warrant inducement transaction By Investing.com - Investing.com Nigeria
AIM ImmunoTech raises $3.6 million through warrant inducement transaction - Investing.com
AIM ImmunoTech Raises Capital Through Warrant Exercise Inducement - TipRanks
Orca Capital reports 1.79M shares in AIM ImmunoTech (NASDAQ: AIM) - Stock Titan
AIM ImmunoTech (NYSE: AIM) gets $3.6M from warrant exercise inducement deal - Stock Titan
MSN Money - MSN
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):